Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2021 | $14.00 | Market Perform → Outperform | Raymond James |
| 9/21/2021 | $29.00 | Buy | BWS Financial |
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
4 - PLx Pharma Inc. (0001497504) (Issuer)
SC 13G - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -
Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00
BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c
15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)
-SEC Filing
-SEC Filing
SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec